Bluejay Diagnostics (NASDAQ:BJDX) Shares Up 12.7%

Shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) traded up 12.7% during mid-day trading on Monday . The stock traded as high as $0.65 and last traded at $0.62. 41,154 shares were traded during trading, a decline of 12% from the average session volume of 46,850 shares. The stock had previously closed at $0.55.

Bluejay Diagnostics Stock Down 12.0 %

The business has a fifty day moving average price of $0.75 and a 200-day moving average price of $1.88. The company has a market cap of $1.48 million, a P/E ratio of -0.06 and a beta of 0.85.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($1.10).

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 24,230 shares of the company’s stock, valued at approximately $30,000. Armistice Capital LLC owned 1.95% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. 18.47% of the stock is owned by institutional investors and hedge funds.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.